



**ESMO** GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE

**35**  
years

**ES**  
European  
School  
of  
Oncology  
Learning to care

# 3<sup>RD</sup> ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY

**26-30 April 2017**  
**San Jose, Costa Rica**

**Chairs:**

A. Cervantes, ES - N. Pavlidis, GR  
R.A. Stahel, CH

**Scientific Co-ordinators:**

M. Aapro, CH - F. Cardoso, PT

Under the auspices of



**LATIN-AMERICA PROGRAMME**

## FOREWORD

The Masterclass is the most structured ESO educational activity whose format has been established and presented in Europe for over a decade. The success of the teaching method has been confirmed by the events held also in other parts of the world as well as by the first and second edition of the Latin American Masterclass held in Brazil and Colombia in 2015 and 2016. It is with pleasure and gratefulness for the consideration of the local community, that ESO announces the third edition to be held in the region in 2017. The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based guidelines will be cited. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairs and the faculty. As for all Masterclasses, the number of participants will be limited and admission will be by competitive application only. Admitted participants will be granted free registration and full-board accommodation for the duration of the Masterclass.

## TEACHING FORMAT

The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. The clinical sessions will be complemented by tumour board discussions supported by regional tutors. Furthermore, participants will deliver case presentations within small groups and discuss these with the chairs and the faculty. In preparation of the attendance, participants will be requested to follow four selected e-ESO sessions ([www.e-eso.net](http://www.e-eso.net)). All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.

## LEARNING OBJECTIVES

- Improve medical oncologists' skills
- Practising case discussions
- Deep focus on breast, gastro-intestinal, genitourinary, gynaecological, head and neck and lung cancers
- Compact update on further topics of interest

## THE MASTERCLASS IS:

- A 5-day residential educational event
- Full immersion
- Clinically-oriented
- Multidisciplinary
- Delivered by an international faculty of experts

## IDEAL PROFILE OF THE MASTERCLASS CANDIDATE

- Age between 30 and 40 years
- At least 2-3 years' experience in medical oncology
- Involvement in scientific activities (desirable)
- At least an intermediate level of English language (simple scientific discussion in English)
- Practicing in Latin-America

## LANGUAGE

The Masterclass will be held in English and translation will not be provided.

## INSURANCE

The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants will be advised to take out their own personal and travel insurance coverage.

## CME ACCREDITATION AND CERTIFICATES

Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME). EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). Information on the status of the applications can be obtained from the organising secretariat. Participants will be entitled to receive a certificate of attendance at the close of the event by completing the on-line evaluation questionnaire.

## **FACULTY** *(as of October 2016)*

**M.S. Aapro**, Clinique de Genolier, Genolier, CH

**F. Calvo**, Hospital General Universitario Gregorio Marañón, Madrid, ES

**E. Cambroner**, Centro de Cancer Metropolitano, San Jose, CR

**F. Cardoso**, Champalimaud Cancer Center, Lisbon, PT

**P. Casali**, National Cancer Institute, Milan, IT (in videoconference)

**F. Cavalli**, Oncology Institute of Southern Switzerland, Bellinzona, CH

**A. Cervantes**, University Clinical Hospital, Valencia, ES

**L. Corrales**, CCSS (Caja Costaricense de Seguro Social), San Jose, CR

**G. Curigliano**, European Institute of Oncology, Milan, IT

**M. Del Pilar Estevez Diz**, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR

**S.X. Franco**, Clinical del Country, Bogota, CO

**A. Frasson**, Hospital Israelita Albert Einstein, Sao Paulo, BR

**J.P. Garbanzo**, CCSS (Caja Costaricense de Seguro Social), San Jose, CR

**F. Geara**, The American University of Beirut Medical Center, Beirut, LB

**F. Gomez**, Fundacion Santa fe de Bogota, CO

**J. Jeronimo**, PATH, Seattle, US

**S. Litière**, European Organisation for Research and Treatment of Cancer EORTC, Brussels, BE

**C. Medina**, Fundacion santa fe de Bogota, CO

**N. Mottet**, University Jean Monnet, Saint Etienne, FR

**N. Pavlidis**, University Hospital, Ioannina, GR

**F.A. Peccatori**, European School of Oncology and European Institute of Oncology, Milan, IT

**F. Penault-Llorca**, Centre Jean Perrin, Clermont-Ferrand, FR

**R.A. Stahel**, University Hospital, Zurich, CH

**R.M. Terra**, University of São Paulo Medical School, São Paulo, BR

**E. Van Cutsem**, University Hospital Gasthuisberg, Leuven, BE

**J.B. Vermorken**, University Hospital Antwerp, Edegem, BE

**S. Wang**, CCSS (Caja Costaricense de Seguro Social), San Jose, CR

**G. Werutsky**, German Breast Group (GBG), Neu-Isenburg, DE

**Z. Zeledon**, University of Costa Rica, Hospital San Juan de Dios, San Jose, CR

# PRELIMINARY PROGRAMME

## Wednesday, 26 April

---

- 14:15** *Welcome and introduction* Chairs and Coordinators
- 14:25** *Spotlight session*  
• The magnitude of the cancer problem in my country Speaker to be confirmed  
• *Discussion*
- 14:55** *Clinical session* **Genito-urinary cancers (I)** *Chair: N. Mottet, FR*  
Prostate cancer:  
• Active surveillance or watchful waiting F. Gomez, CO  
• Local therapy: Surgery and radiotherapy F. Geara, LB  
• First-line endocrine treatment N. Mottet, FR  
• Endocrine-resistant-refractory N. Mottet, FR  
• *Discussion*
- 17:15** *Coffee break*
- 17:30** *Clinical session* **Genito-urinary cancers (II)** C. Medina, CO  
• Treatment of bladder cancer N. Mottet, FR  
• Metastatic renal cancer: Evidence-based treatment C. Medina, CO  
• *Discussion*
- 19:10** *Tumour board* **Genito-urinary cancers** *Faculty and local tutor:*  
• Participants' case presentations F. Gomez, CO - C. Medina, CO
- 20:30** *Welcome dinner*

## Thursday, 27 April

---

- 8:30** *Clinical session* **Breast cancer (I)** *Chair: G. Curigiano, IT*  
• What the clinician needs to know about breast pathology and sample quality F. Penault-Llorca, FR  
• (Neo-) adjuvant chemotherapy and biological agents G. Curigiano, IT  
• (Neo-) adjuvant endocrine therapy F. Cardoso, PT  
• Optimal loco-regional management of breast cancer A. Frasson, BR  
• *Discussion*
- 10:30** *Coffee break*
- 10:50** *Clinical session* **Breast cancer (II)** *Chair: F. Cardoso, PT*  
• Recommended management of HER-2+ advanced breast cancer F. Cardoso, PT

- Recommended management for triple-negative advanced breast cancer
- Recommended management for ER+ advanced breast cancer
- *Discussion*

G. Curigliano, IT

S.X. Franco, CO

**12:30 Tumour board Breast cancer**

- Participant's case presentations

*Moderator:* M.S. Aapro, CH

*Faculty and tutor:* A. Frasson, BR  
S.X. Franco, CO

**13:30 Lunch**

**14:30 Spotlight session Clinical trial management**

- The reality of clinical trials in Latin America
- Critically assessing published clinical trials: The danger of bias and wrong interpretations
- *Discussion*

*Chair:* F. Cardoso, PT

G. Werutsky, DE

S. Litière, BE

**16:00 Coffee break**

**16:20 Spotlight session**

- Management of cancer in young women
- Discussion

F. Cardoso, PT

**17:00 Spotlight session**

- Fertility preservation and cancer in pregnancy
- Discussion

F.A. Peccatori, IT

**17:55- Spotlight session**

- 18:50**
- Management and treatment of toxicity
  - *Discussion*

M.S. Aapro, CH

**Friday, 28 April**

---

**8:30 Clinical session Gynaecological cancers**

- New classification of gynaecologic cancers
- Ovarian cancer: Surgical and systemic treatment
- Cervical cancer: Systemic treatment
- Cervical cancer: Primary and secondary prevention
- Management of endometrial cancer
- Radiotherapy of gynaecological malignancies
- *Discussion*

*Chair:* J.B. Vermorken, BE

F. Penault-Llorca, FR

J.B. Vermorken, BE

M. del Pilar Estevez Diz, BR

J. Jeronimo, US

J.B. Vermorken, BE

F. Geara, LB

**11:20 Coffee break**

<b>11:40</b>	<i>Tumour board</i> <b>Gynaecological cancers</b> • Participant's case presentations	<i>Faculty and tutor:</i> M. del Pilar Estevez Diz, BR
<b>12:10</b>	<i>Spotlight session</i> <b>Cancer of unknown primary</b> • Discussion	N. Pavlidis, GR
<b>12:50</b>	<i>Lunch</i>	
<b>14:00</b>	Clinical session <b>Head and neck cancer</b> • When to operate? • When to irradiate? • Systemic therapy and radio-chemotherapy • Discussion	<i>Chair:</i> J.B. Vermorken, BE E. Cambronero, CR F. Calvo, ES J.B. Vermorken, BE
<b>16:05</b>	<i>Tumour board</i> <b>Head and neck cancer</b> • Participant's case presentations	<i>Faculty and local tutor:</i> E. Cambronero, CR
<b>16:40</b>	<i>Coffee break</i>	
<b>17:00-</b>	<b>Group sessions (three/four groups)</b>	Chairs and Coordinators, and regional tutor for each group
<b>19:00</b>	• <b>Part I:</b> Clinical case presentations by participants • <b>Part II:</b> Selected participants present their national situation ("How is cancer treated in my country")	<i>Tutors:</i> J. Baptista, CR L. Corrales, CR - S. Wang, CR
<b>Saturday, 29 April</b>		
<b>8:30</b>	Clinical session <b>Gastro-intestinal tumours (I)</b> • Adjuvant and neo-adjuvant treatment of colorectal cancer • Systemic treatment in advanced disease (including liver) • Discussion	<i>Chair:</i> A. Cervantes, ES  E. Van Cutsem, BE  E. Van Cutsem, BE
<b>9:50</b>	<i>Coffee break</i>	
<b>10:10</b>	Clinical session <b>Gastro-intestinal tumours (II)</b> • Management of early rectal cancer: Any role for adjuvant chemotherapy? • Systemic treatment in early and advanced gastric cancers and esophageal cancer • Pancreatic and biliary tract cancers • Discussion	<i>Chair:</i> E. Van Cutsem, BE  A. Cervantes, ES  A. Cervantes, ES E. Van Cutsem, BE
<b>12:10</b>	<i>Tumour board</i> <b>Gastro-intestinal tumours</b> • Participant's case presentations	<i>Faculty and tutor:</i> J.P. Garbanzo, CR - Z. Zeledon, CR
<b>13:10</b>	<i>Lunch</i>	



<b>14:10</b>	<i>Spotlight session</i>	
	<ul style="list-style-type: none"> <li>• ESMO guidance on evaluation of treatment benefit</li> <li>• Discussion</li> </ul>	R.A. Stahel, CH
<b>14:50</b>	<i>Spotlight session</i>	
	<ul style="list-style-type: none"> <li>• MALT lymphoma</li> <li>• Discussion</li> </ul>	F. Cavalli, CH
<b>15:30</b>	<i>Spotlight session</i>	
	<ul style="list-style-type: none"> <li>• Sarcoma and GIST</li> <li>• Discussion</li> </ul>	P. Casali, IT (videoconf.)
<b>16:10</b>	<i>Coffee break</i>	
<b>16:30</b>	<b>Group sessions (three/four groups)</b>	Chairs and Coordinators, and regional tutor for each group
	<ul style="list-style-type: none"> <li>• <b>Part I:</b> Clinical case presentations by participants</li> <li>• <b>Part I:</b> Selected participants present their national situation ("How is cancer treated in my country")</li> </ul>	<i>Tutors:</i> J. Baptista, CR L. Corrales, CR - S. Wang, CR
<b>19:30</b>	<i>Departure to the dinner</i>	
<b>20:00</b>	<i>Farewell dinner</i>	

## Sunday, 30 April

---

<b>8:30</b>	<i>Clinical session</i> <b>Lung cancer (I)</b>	<i>Chair:</i> R.A. Stahel, CH
	<ul style="list-style-type: none"> <li>• Molecular classification of lung cancer for clinical practice</li> <li>• Surgery</li> <li>• Radiotherapy</li> <li>• Non-small cell lung cancer systemic therapy</li> <li>• Discussion</li> </ul>	F. Penault-Llorca, FR R.M. Terra, BR F. Calvo, ES R.A. Stahel, CH
<b>11:00</b>	<i>Coffee break</i>	
<b>11:20</b>	<i>Clinical session</i> <b>Lung cancer (II)</b>	<i>Chair:</i> R.A. Stahel, CH
	<ul style="list-style-type: none"> <li>• Small cell lung cancer</li> <li>• Discussion</li> </ul>	R.A. Stahel, CH
<b>11:55</b>	<i>Tumour board</i> <b>Lung cancer</b>	<i>Faculty and tutor:</i>
	<ul style="list-style-type: none"> <li>• Participant's case presentations</li> </ul>	R. Terra, BR - L. Corrales, CR
<b>12:55</b>	<i>Learning assessment test</i>	
<b>13:40-14:40</b>	<i>Lunch followed by departures</i>	

# GENERAL INFORMATION

## ORGANISING SECRETARIAT

European School of Oncology

Piazza Indipendenza 2 | 6500 Bellinzona | Switzerland

Luis Carvalho | Ph: +41 91 820 09 58 | E-mail: [lcavalho@eso.net](mailto:lcavalho@eso.net)

Laura Richetti | Ph: +41 91 820 0951 | E-mail: [lrchetti@eso.net](mailto:lrchetti@eso.net)

### ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY

Successful applicants are granted free registration and accommodation

**APPLICATION DEADLINE: 15 JANUARY 2017**

Information and online application are available at [www.eso.net](http://www.eso.net)

## HOW TO APPLY

Interested oncologists should apply and provide the following documents:

- Letter describing motivation for attending;
- Support letter from head of department or mentor;
- CV with list of publications (if the list is not provided, it will be assumed that no papers have been published);
- Clinical case abstract (see below).

### Clinical case abstract

Applicants are requested to submit an abstract describing a clinical case related to one of the subjects of the Masterclass (breast, gastro-intestinal, genito-urinary, gynaecological, head and neck, and lung cancers). It is suggested that, among the subjects of the Masterclass, the clinical case is on a tumour type that the applicant does not see frequently but that could add to the overall educational contents of the Masterclass. On the contrary, it is recommended that the case reflects the participant's daily practice, avoiding uncommon or extremely rare cases which may have a lower educational impact. The clinical case abstract should include diagnostic considerations, treatment, results and follow-up, at least three questions proposed for discussion. Admitted participants will have the opportunity to present the clinical case in the format of a clinical grand round discussion to the chairs, tutors, other faculty members and participants. The one-page abstract should be submitted on-line using the template available at [www.eso.net](http://www.eso.net), or by entering it in the application form.

### Application instructions

Applications may be submitted on-line or by filling out the application form and sending it, together with the required documents, by e-mail.

#### ***Apply on-line***

In the Application page of <http://bit.ly/zdSjPYo> please download the "Template for professional experience" and "Template for clinical case abstract". Fill them out and have them ready on your computer.

Select "Individual registration" to subscribe to the website. When your access data is provided, please log-in and upload the required documents, including the two templates.

#### ***Apply by e-mail***

The application form can be downloaded from the Application page at [www.eso.net](http://www.eso.net).

Fill out the form and save it on your computer. The clinical case abstract should be entered in the appropriate page of the form. Send the completed application form and the required documents by e-mail to [lrchetti@eso.net](mailto:lrchetti@eso.net). The application outcome will be notified by e-mail by mid-February.